Quantitative Systems Pharmacology (QSP) modelling specialist InSysBio announced on Wednesday an extension of its collaboration with oncology company BeOne Medicines.

In this project, mechanistic translational modelling will be applied to support the selection of minimal recommended starting dose and step-up dosing regimen to mitigate cytokine release syndrome and optimise dose-escalation clinical study design.

Oleg Demin Jr, head of Oncology and Immuno-Oncology, InSysBio, said: "Nowadays, trimer-based mechanistic modelling has become an essential tool to guide the selection of an appropriate starting dose for first-in-human trials of T-cell engagers, ensuring the dose is high enough to be effective while avoiding sub-therapeutic levels and multiple dose escalation steps. InSysBio's generic QSP model for T-cell engagers mechanistically captures the difference between in vitro and clinical settings, supporting precise preclinical-to-clinical translation. Consequently, it allows prediction of not only the starting dose but also the step-up dosing regimen based on preclinical data."